The News

Innate Pharma S.A. announced two additional clinical trials for its IPH 1101 drug candidate

26/04/2007

Innate Pharma S.A. today announced two additional clinical trials for its IPH 1101 drug candidate, which is already in Phase II metastatic renal cell carcinoma (MRCC) trials. The new target indications are follicular non-Hodgkin's lymphoma (“fNHL”) and viral hepatitis C (“HCV”). The HCV trial will be Innate’s first outside the field of oncology.

"These milestones are in line with what we announced during our IPO in November 2006: with two drug candidates in clinical trials and a multi-indications program, we are moving forward with our business plan" stated Hervé Brailly, CEO of Innate Pharma.

Please find more information in the press release enclosed.

2007

Click here for the site of Sofinnova Ventures, our sister firm in San Francisco http://www.sofinnova.com